牛津大学启动尼帕病毒疫苗人体试验。 University Of Oxford Launches Human Trials For Nipah Virus Vaccine.

牛津大学的研究人员已经开始针对尼帕病毒疫苗进行首次人体试验，尼帕病毒是一种致命疾病，死亡率为 75%，影响到包括印度在内的多个亚洲国家。 Oxford researchers have commenced the first-ever human trials for a vaccine targeting the Nipah virus, a deadly disease with a 75% fatality rate, which affects several Asian countries, including India. 尼帕病毒通过与受感染的动物接触或人与人之间的密切接触传播。 The Nipah virus is transmitted through contact with infected animals or by person-to-person close contact. 目前，这种疾病还没有批准的疫苗或治疗方法，世界卫生组织已将其确定为紧急研究的优先事项。 Currently, there are no approved vaccines or treatments for this disease, which the World Health Organization has identified as a priority for urgent research. 该疫苗试验由 CEPI 资助，使用与牛津/阿斯利康 COVID-19 疫苗相同的病毒载体平台，最终目标是预防局部疫情并为未来的大流行做好准备。 The vaccine trial, funded by CEPI, uses the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine and will ultimately aim to prevent local outbreaks and prepare for future pandemics.